兰地洛尔临床应用中国专家共识.pdf

·指南与共识· 兰地洛尔临床应用中国专家共识 中国医师协会心力衰竭专业委员会 国家心血管病专家委员会心力衰竭专业委员会 中华心力衰竭和心肌病杂志编委会 【摘要】 兰地洛尔是新一代速效、超短效、高选择性β受体阻滞剂，对心脏抑制作用弱且较少引 1 起低血压。国内医师对兰地洛尔的认识和用药经验相对匮乏。为使临床医师更充分了解和合理使用 兰地洛尔，中国医师协会心力衰竭专业委员会组织国内该领域专家制定了本共识。本共识从兰地洛 尔的药代动力学和药理作用，以及在快速心律失常、急性冠状动脉综合征、急性失代偿性心力衰竭、围 术期综合应用、严重脓毒症/脓毒性休克等方面的临床应用做以详尽阐述，旨在指导临床医师合理、规 范用药。 【关键词】 静脉β肾上腺素能受体阻滞剂； 兰地洛尔 Chinese Expert Consensus on the Clinical Application of Landiolol Chinese Heart Failure Association of Chinese Medical Doctor Association, National Expert Committee on Cardiovascular Diseases and Professional Committee on Heart Failure, Editorial Board of Chinese Journal of Heart Failure and Cardiomyopathy Corresponding author: Zhang yuhui, E‐mail:yuhuizhangjoy@ 163.com 【Abstract 】 Landilol is a new generation of fast acting, ultra‐short acting and highly selective β1 receptor blocker, which has weak cardiac inhibition and less hypotension. Domestic doctors are relatively short of knowledge and experience on landilol. In order to enable clinicians to fully understand and rationally use landiolol, the Chinese Heart Failure Association of the Chinese Medical Doctor Association organized domestic experts in this field to formulate this consensus. This consensus will introduce the pharmacokinetics and pharmacological effects of landiolol, and elaborate the clinical application of landiolol in tachyarrhythmia, acute coronary syndrome, acute decompensated heart failure, perioperative comprehensive application, severe sepsis/septic shock, etc, in order to guide the reasonable use of landiolol for clinical physicians. 【Key words 】 Intravenous β‐adrenergicreceptorblocker; Landilol 静脉β肾上腺素能受体阻滞剂（β受体阻滞剂） 该领域专家经反复讨论，并参考国外循证医学证据 在临床研究中取得了一些新证据，其疗效和安全性 和指南制定了本共识。 得到一定的肯定，适用人群和用法